# Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia

> **NCT07491263** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University** · enrollment: 6 (estimated)

## Conditions studied

- Relapsed/Refractory CD19-positive B-ALL

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** QH103 Cell Injection

## Key facts

- **NCT ID:** NCT07491263
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07491263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07491263, "Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07491263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*